Last month, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) released its safety review of incretin-based therapies for diabetes. It...
Complications
Higher blood sugar levels cause damage over time to blood vessels and nerves, which can affect your eyes, heart, kidneys, and other organs. It’s important to be aware of these diabetes-related health complications so that you can act now to avoid them or prevent them from progressing.
37 readers recommended
Last month, in early September, results from the DPP-4 inhibitor cardiovascular outcomes trials SAVOR-TIMI 53 (for Bristol Myers Squibb and AstraZeneca’s Onglyza) and...
38 readers recommended
In February, Johnson and Johnson announced that its SGLT-2 inhibitor for type 2 diabetes, Invokana (canagliflozin), will undergo trials as a treatment for diabetic...
30 readers recommended
Update (1/12/15): Medtronic Diabetes gave an update on their upcoming diabetes device pipeline at the J.P. Morgan Healthcare Conference. The MiniMed 640G is expected to...
26 readers recommended
On June 11, Glooko and the Joslin Diabetes Center announced the release of their HypoMap software , a cool product that really should be able to identify and help...
18 readers recommended
The curious milestone of a diabetes anniversary.
17 readers recommended
How a major research study is challenging an outdated FDA restriction.
18 readers recommended
Why these two seemingly different diseases may be more similar than you think.
19 readers recommended
By Kelly Close Twitter Summary: @kellyclose speaks to @US_FDA in favor of PCSK9 inhibitor drug Praluent – need to bring more options to #PWD to fight against CV disease...
13 readers recommended
Can a drug long-used to treat gout be effective at preventing diabetic kidney disease?
16 readers recommended
One of the highlights of this year’s ADA Exhibit Hall was NeuroMetrix’s Quell chronic pain management device. Quell is the over the counter version (no prescription...
23 readers recommended
Expansion of the use of Roche’s Lucentis a major step for patients.
15 readers recommended
How will a new drug fare in a 4,000-patient, four-year study?
17 readers recommended
Our overview of what all of us need to know about one of our most vital organs – our kidneys.
23 readers recommended
Current trial results show that obese patients using Contrave are about 41% less likely to experience any major heart event (e.g. heart attack, strokes, or heart-related...
22 readers recommended
How these two FDA-submitted drugs could address this major healthcare need.
15 readers recommended
Over seven million Americans have diabetic retinopathy – how Eylea provides another treatment for this serious complication.
15 readers recommended
$300 million and counting – how much have we learned from the heart safety trials of Onglyza and Nesina?
36 readers recommended
Our deep dive on a new therapy now available in Europe – the benefits, risks, and when it might come to the US.
13 readers recommended
How this new option makes it easier to diagnose this major diabetes complication.